obi-833
Vaccineexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2015 (NCT02310464)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigen
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- obi-833
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06490198 | Phase 1 | Jul 31, 2024 | Chang Gung University |
| NCT05376423 | Phase 2 | Jun 2, 2022 | National Taiwan University |
| NCT02310464 | Phase 1 | Dec 1, 2015 | Gabrail Cancer Center, Mary Crowley Cancer Center, National Taiwan University, OBI Pharma, Inc, Taipei Medical University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Taiwan University | Academic/Hospital | 2 | 1 | 2 | 2015 |
| Chang Gung University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Gabrail Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Mary Crowley Cancer Center | Academic/Hospital | 1 | 0 | 1 | 2015 |
| OBI Pharma, Inc | For profit | 1 | 1 | 1 | 2015 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2015 |
6 organizations
Page 1 / 1